Alnylam Pharmaceuticals, Inc. (ALNY) Down 25.0% — Do I Admit Defeat and Sell?
Alnylam Pharmaceuticals, Inc. (ALNY) is struggling in Thursday's session, last trading at $174.34 on the NASDAQ. That is a $58.06 decline from the prior close of $232.40, erasing roughly a quarter of the company's market value in a single session. The selloff deepens a long slide for the stock, which now trades about 64.0% below its 52-week high of $484.61, a level reached on October 28, 2025. A $31.10 billion market cap still makes Alnylam one of the larger names in biotech, but the stock has given back most of the premium it carried a year ago.
Volume is running at roughly 6.68 million shares against a 90-day average of about 1.68 million, close to four times normal turnover. Selling at that scale on a decline of this size points to broad repositioning rather than routine trading.
Why Alnylam Pharmaceuticals, Inc. Price is Moving Lower
Today's collapse comes from Alnylam's Q3 report and, more specifically, from what management said about the months ahead. The headline figures looked strong. Revenue came in at $1.458 billion, ahead of the $1.45 billion Zacks estimate and up 16.7% year over year. Non-GAAP diluted EPS of $16.26 dwarfed the $2.19 consensus, but that figure was inflated by a $1.9 billion non-cash tax benefit from releasing a tax valuation allowance. That accounting item also lifted GAAP net income to $2.17 billion, compared with $292.7 million a year earlier. Strip away the tax benefit and the quarter's real story sits in the TTR franchise, where sales of $1.15 billion missed the $1.17 billion estimate. AMVUTTRA, the franchise's main growth driver, generated $1.13 billion against expectations of $1.15 billion.
The earnings call turned a modest miss into a guidance problem. Management said physician outreach for AMVUTTRA is growing but that turning that interest into patient starts is taking longer than expected. It also said it does not expect faster growth in the fourth quarter. The company kept its 2026 TTR sales guidance of $4.2 billion to $4.5 billion but signaled results should land near the low end of that range. Payer pressure is part of the picture: on October 1, first-line AMVUTTRA access for Medicare Advantage patients was tightened, a restriction that weighs directly on the conversion problem management described.
Management added two more layers of uncertainty. It warned that a proposed 340B reimbursement rule, which would take effect January 1, 2027 if finalized, could disrupt hospital ordering during Q4. It also pushed its 2027 revenue guidance out to mid-February. For a stock priced on the strength of its commercial ramp, slower patient conversion, tighter payer access, and a delayed outlook together hit the core of the investment case. The move is clearly company-specific: Merck & Co., Inc. (MRK) gained 4.29% and Gilead Sciences, Inc. (GILD) rose 1.34% in the same session, so the broader Health Care group offered no cover.
What is the Alnylam Pharmaceuticals, Inc. Rating - Should I Sell?
Weiss Ratings assigns ALNY a C rating. Current recommendation is Hold. That rating reflects a company whose underlying business has scaled rapidly but whose stock has delivered a punishing experience for shareholders. Today's guidance-driven selloff reinforces both sides of that tension.
The fundamental strengths are real. The Excellent rating on the Growth Index is supported by revenue growth of 66.86%, an exceptional pace for a company that has moved from a pipeline-driven story to a commercial franchise anchored by AMVUTTRA. Still, the 16.7% year-over-year gain in the latest quarter is a much slower pace, and management's comments suggest that deceleration may persist into year-end. The Excellent rating on the Solvency Index shows a balance sheet that can fund continued commercial investment and pipeline development without strain. That matters because Alnylam now faces payer friction and possible reimbursement disruption that could slow cash generation in the near term.
Where the picture becomes more nuanced is the Efficiency Index, rated Fair. A reported ROE of 100.70% looks extraordinary on its face, but it is magnified by a relatively thin equity base and recent tax-related accounting effects rather than by consistently high operating returns. The 16.81% profit margin gives the more realistic read. Alnylam is now solidly profitable, but its margins are still maturing toward what an established specialty drugmaker would typically report. With a forward P/E of 39.22, the stock also continues to price in execution that today's call made harder to count on.
The Weak ratings on the Total Return Index and the Volatility Index capture what shareholders have actually lived through. A stock trading roughly 64% below its 52-week high has not rewarded holders over the measurement period. A one-day decline of nearly 25% on slower AMVUTTRA patient starts and an uncertain reimbursement outlook shows why the Volatility Index is not rated higher. These two dimensions are the main reason the overall rating stops at C. Within the Health Care sector, Alnylam sits alongside Merck & Co., Inc. (MRK, C), Gilead Sciences, Inc. (GILD, C), and Regeneron Pharmaceuticals, Inc. (REGN, C). Those larger, more diversified drugmakers lack the single-franchise concentration that left Alnylam so exposed today.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) is a Health Care company and the leading commercial developer of RNA interference (RNAi) therapeutics. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam designs medicines that silence the genes responsible for producing disease-causing proteins. This approach targets illness at its genetic source rather than treating downstream symptoms. The company spent well over a decade proving out the platform before converting it into a portfolio of approved, revenue-generating drugs.
The transthyretin (TTR) franchise is the commercial core of the business. AMVUTTRA (vutrisiran) treats transthyretin-mediated amyloidosis and has expanded beyond polyneuropathy into ATTR cardiomyopathy, a much larger patient population. That expansion has made AMVUTTRA the company's dominant revenue source. ONPATTRO (patisiran), Alnylam's first approved RNAi therapy, also addresses hereditary ATTR amyloidosis. Beyond TTR, the company markets GIVLAARI (givosiran) for acute hepatic porphyria and OXLUMO (lumasiran) for primary hyperoxaluria type 1, and it earns royalties on Leqvio (inclisiran), the cholesterol-lowering therapy commercialized by Novartis.
Alnylam's competitive advantages rest on its deep RNAi intellectual property, its validated delivery technology, and infrequent dosing. AMVUTTRA, for example, is administered once every three months, a convenience edge in chronic disease management. The pipeline extends the platform into next-generation TTR candidates and larger indications such as hypertension and neurodegenerative disease, some of which are being developed with large pharmaceutical partners. The ATTR cardiomyopathy market is competitive, though, with established and newer oral therapies from rival drugmakers. Payer access decisions and reimbursement policy carry outsized weight for a company that depends so heavily on one franchise.
Investor Outlook
Alnylam (ALNY) remains a fast-growing, well-capitalized RNAi leader, but slowing AMVUTTRA patient conversion, tighter Medicare Advantage access, and an unresolved 340B rule justify a cautious stance at its C (Hold) rating. Investors should watch whether Q4 TTR sales hold the low end of the $4.2 billion to $4.5 billion guidance, how the 340B proposal is resolved before its January 1, 2027 effective date, and what management lays out when it issues 2027 revenue guidance in mid-February. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--